

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 3rd July 2024

Classification of products:

G **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug.

ASR

Amber Specialist Recommendation drug - Can be recommended by a specialist for initiation in primary care.

ASI

Amber Specialist Initiation drug – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.

ASC

Amber Shared Care drug - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.

R

Red drug - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.

BLACK Not Approved - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.

GREY Not Reviewed - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
None				
2) New Requests				
None				
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA967: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA972: Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA973: Atogepant for preventing migraine	✓ ASI			The formulary will reflect the TAG – ICB is the responsible commissioner. Referred to IPMOC for final approval due to cost impact on primary care.
TA974: Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA975: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA976: Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA977: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA978: Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (update) TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (update) TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (update)	✓ R			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA616: Cladribine for treating relapsing–remitting multiple sclerosis (update) TA312: Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (update) TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (update)	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
HST31: Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
CNS chapter of harmonised NY&Y formulary	✓			

The following documents/guidelines were presented to and approved at the July 2024 meeting of the APC:

- NY&Y Guideline for use – Use of aspirin in pregnancy to reduce the risk of pregnancy complications (including preeclampsia and fetal growth restriction)
- HNY Blood Glucose Meter Formulary (updated)

DECISION SUMMARY

- NY&Y APC guidelines for defining RAG status (updated)

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the July 2024 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the July 2024 meeting of the APC:

- Nil

The following documents/guidelines were presented to the July 2024 meeting of the APC for comment:

- HNY Shared Care Protocol: Valproate Medicines for Patients of Child-Bearing Potential